Contributors |
|
xi | |
Series Foreword |
|
xvii | |
Preface |
|
xix | |
Acknowledgments |
|
xxi | |
|
I Epidemiology, Screening, and Diagnosis |
|
|
|
1 Introduction: The Multidisciplinary Approach to Prostate Cancer |
|
|
3 | (64) |
|
|
2.1 Epidemiology of Prostate Cancer |
|
|
11 | (14) |
|
|
|
2.2 Diet and Prostate Cancer |
|
|
25 | (8) |
|
|
2.3 Epidemiology: Obesity as a Risk Factor |
|
|
33 | (20) |
|
|
|
3.1.1 Screening and Diagnosis: The Pros of PSA Screening |
|
|
37 | (6) |
|
|
|
|
|
3.1.2 The Argument Against Prostate Cancer Screening |
|
|
43 | (6) |
|
|
3.1.3 How Do We Improve PSA Accuracy? |
|
|
49 | (4) |
|
|
|
3.2 Screening and Diagnosis: An Update on the ISUP-Modified Gleason Score and Its Controversies |
|
|
53 | (6) |
|
|
|
3.3 Evaluation of Distant Disease: The Utility of Nuclear Imaging |
|
|
59 | (8) |
|
|
|
|
|
|
4 Current Approaches to Prostate Cancer Staging and Risk Stratification: In the Midst of a Paradigm Shift |
|
|
67 | (48) |
|
|
|
5.1 Novel Molecular and Genotype Profiling in Prostate Cancer: The Future of Screening, Diagnosis, and Staging |
|
|
77 | (8) |
|
|
|
|
|
|
5.2 Genomics and Risk Assessment |
|
|
85 | (8) |
|
|
|
|
5.3 Future Direction: Novel Urine and Serum Markers |
|
|
93 | (4) |
|
|
5.4 Morphometric and Systems Pathology: The Future of Screening, Diagnosis, and Staging |
|
|
97 | (18) |
|
|
|
|
|
|
5.5.1 PET: The Future of Screening, Diagnosis, and Staging for Prostate Cancer |
|
|
101 | (5) |
|
|
|
|
|
|
5.5.2 DCE MRI and MR Spectroscopy: The Future of Screening, Diagnosis, and Staging |
|
|
106 | (3) |
|
|
|
5.5.3 Future Direction: Contrast Ultrasound |
|
|
109 | (6) |
|
|
|
|
6 Counseling Patients With Clinically Localized, High-Risk Prostate Cancer |
|
|
115 | (10) |
|
|
|
II Treatment for Low-Risk, Localized Disease |
|
|
|
7 Active Surveillance for Prostate Cancer: An Overview |
|
|
125 | (8) |
|
|
8 Treatment of Low-Risk, Localized Prostate Cancer: A Holistic Approach With Diet |
|
|
133 | (114) |
|
|
|
|
9.1 Traditional Radical Prostatectomy |
|
|
143 | (6) |
|
|
|
9.2 Laparoscopic Radical Prostatectomy: Techniques and Complications |
|
|
149 | (12) |
|
|
|
9.3 Robotic Radical Prostatectomy: The Thomas Jefferson University Experience |
|
|
161 | (4) |
|
|
|
9.4 Surgical Training, Digital Capture, Virtual Reality, and the Future of Radical Prostatectomy |
|
|
165 | (36) |
|
|
10.1.1 External Beam Radiation Therapy: Conventional Fractionation |
|
|
169 | (10) |
|
|
|
10.1.2 Hypofractionated Radiation Therapy for Localized Prostate Cancer |
|
|
179 | (9) |
|
|
|
10.1.3 Stereotactic Body Radiation Therapy for Localized Prostate Cancer |
|
|
188 | (8) |
|
|
|
10.1.4 Treatment of Low-Risk, Localized Prostate Cancer: Use of Proton Therapy |
|
|
196 | (5) |
|
|
|
|
10.2 Treatment of Low-Risk, Localized Prostate Cancer: Brachytherapy |
|
|
201 | (6) |
|
|
11.1 Treatment of Low-Risk, Localized Prostate Cancer: General Principles of Ablative and Focal Therapies |
|
|
207 | (8) |
|
|
|
|
11.2 Hyperthermia for Prostate Cancer |
|
|
215 | (4) |
|
|
11.3 Ablative Techniques: Vascular Targeted Photodynamic Therapy |
|
|
219 | (4) |
|
|
|
11.4 Laser Ablative Techniques for Prostate Cancer |
|
|
223 | (4) |
|
|
|
11.5 Irreversible Electroporation (IRE) Prostate Ablation |
|
|
227 | (4) |
|
|
|
12.1 Quality of Life With Surgery |
|
|
231 | (4) |
|
|
|
12.2 Quality of Life With Androgen Deprivation Therapy |
|
|
235 | (4) |
|
|
|
12.3 Quality of Life With External Beam Radiation Therapy |
|
|
239 | (4) |
|
|
|
|
12.4 Quality of Life With Brachytherapy for Low-Risk Localized Prostate Cancer |
|
|
243 | (4) |
|
|
|
13 Role for Comparative Effectiveness Research in Treatment Decision Making |
|
|
247 | (12) |
|
|
|
|
14 Defining Treatment Failure for Localized Prostate Cancer: PSA and Beyond |
|
|
259 | (10) |
|
|
|
|
15 Prognosis After Biochemical Failure and Surrogate Endpoints for Prostate Cancer-Specific Mortality |
|
|
269 | (8) |
|
|
|
III Treatment for High-Risk, Localized, and Locally Advanced Disease |
|
|
|
16 Treatment of High-Risk Prostate Cancer: The Role of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy |
|
|
277 | (8) |
|
|
IV Treatment of Disseminated Disease |
|
|
|
17 Salvage Therapy for Rising PSA |
|
|
285 | (14) |
|
|
18 Metastatic Hormone Sensitive Prostate Cancer |
|
|
299 | (102) |
|
|
|
19.1 Metastatic Castrate-Resistant Prostate Cancer: Mechanisms of Hormone Escape |
|
|
311 | (12) |
|
|
19.2 Metastatic Castrate-Resistant Prostate Cancer: Role of Chemotherapy and Multifaceted Treatment Paradigms |
|
|
323 | (14) |
|
|
|
|
19.3 Metastatic Castrate-Resistant Prostate Cancer: Role of Androgen Signaling Inhibitors |
|
|
337 | (28) |
|
|
|
|
|
19.4.1 Radiation and the Immune System |
|
|
347 | (7) |
|
|
|
19.4.2 Immunotherapy: Agents Targeting Prostate Cancer |
|
|
354 | (11) |
|
|
|
|
|
19.5 Treatment of Bony Metastases: Inhibitors of Bone Resorption |
|
|
365 | (12) |
|
|
|
19.6 Treatment of Bone Metastases: Radiopharmaceuticals |
|
|
377 | (10) |
|
|
|
|
19.7 Prognostication of Metastatic Castration-Resistant Prostate Cancer |
|
|
387 | (14) |
|
|
|
Index |
|
401 | |